Seminars in Hematology
Volume 42, Issue 4 , Pages 221-229 , October 2005

Role of Tyrosine Kinases and Phosphatases in Polycythemia Vera

  • Zhizhuang Joe Zhao

      Affiliations

    • Hematology/Oncology Division, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
    • Corresponding Author InformationAddress correspondence to Zhizhuang J. Zhao, 777, PRB, 2220 Pierce Ave, Nashville, TN 37232-6307
    • ,
  • William Vainchenker

      Affiliations

    • INSERM U362, Institut Gustave Roussy, Villejuif, France
    • Corresponding Author InformationWilliam Vainchenker, INSERM U362, PR1, Institut Gustave Roussy, 39 rue Camile Desmoulins, Villejuif 94805 cedex, France
    • ,
  • Sanford B. Krantz

      Affiliations

    • Hematology/Oncology Division, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
    • ,
  • Nicole Casadevall

      Affiliations

    • INSERM U362, Institut Gustave Roussy, Villejuif, France
    • Hématologie Biologique, Hôpital de l’Hotel Dieu, Paris, France
    • ,
  • Stefan N. Constantinescu

      Affiliations

    • Ludwig Institute for Cancer Research and Christian de Duve Institute of Cellular Pathology and MEXP Unit, Université Catholique de Louvain, Brussels, Belgium

References 

  1. Hunter T . Signaling—2000 and beyond . Cell . 2000;100:113–127
  2. Blume-Jensen P , Hunter T . Oncogenic kinase signalling . Nature . 2001;411:355–365
  3. Manning G , Whyte DB , Martinez R , Hunter T , Sudarsanam S . The protein kinase complement of the human genome . Science . 2002;298:1912–1934
  4. Alonso A , Sasin J , Bottini N , Friedberg I , Friedberg I , Osterman A , et al.   Protein tyrosine phosphatases in the human genome . Cell . 2004;117:699–711
  5. Andersen JN , Jansen PG , Echwald SM , Mortensen OH , Fukada T , Del Vecchio R , et al.   A genomic perspective on protein tyrosine phosphatases (Gene structure, pseudogenes, and genetic disease linkage) . FASEB J . 2004;18:8–30
  6. Bardelli A , Parsons DW , Silliman N , Ptak J , Szabo S , Saha S , et al.   Mutational analysis of the tyrosine kinome in colorectal cancers . Science . 2003;300:949
  7. Wong S , Witte ON . The BCR-ABL story (Bench to bedside and back) . Annu Rev Immunol . 2004;22:247–306
  8. Wang Z , Shen D , Parsons DW , Bardelli A , Sager J , Szabo S , et al.   Mutational analysis of the tyrosine phosphatome in colorectal cancers . Science . 2004;304:1164–1166
  9. Spivak JL . Polycythemia vera (Myths, mechanisms, and management) . Blood . 2002;100:4272–4290
  10. Green AR . Pathogenesis of polycythemia vera . Lancet . 1996;347:844–845
  11. Prchal JF , Prchal JT . Molecular basis for polycythemia . Curr Opin Hematol . 1999;6:100–109
  12. Prchal JF , Axelrad AA . Bone-marrow responses in polycythemia vera . N Engl J Med . 1974;290:1382; (letter)
  13. Fisher MJ , Prchal JF , Prchal JT , D’Andrea AD . Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera . Blood . 1994;84:1982–1991
  14. Correa PN , Eskinazi D , Axelrad AA . Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro (Studies in an improved serum-free medium) . Blood . 1994;83:99–112
  15. Zanjani ED , Lutton JD , Hoffman R , Wasserman LR . Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin . J Clin Invest . 1977;59:841–848
  16. Casadevall N , Vainchenker W , Lacombe C , Vinci G , Chapman J , Breton-Gorius J , et al.   Erythroid progenitors in polycythemia vera (Demonstration of their hypersensitivity to erythropoietin using serum free cultures) . Blood . 1982;59:447–451
  17. Dai CH , Krantz SB , Means RT , Horn ST , Gilbert HS . Polycythemia vera blood burst-forming units erythroid are hypersensitive to interleukin-3 . J Clin Invest . 1991;87:391–396
  18. Dai CH , Krantz SB , Means RT , Horn ST , Gilbert HS . Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor . Blood . 1992;80:891–899
  19. Dai CH , Krantz SB , Green WF , Gilbert HS . Polycythemia vera. III. Burst forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression . Br J Haematol . 1994;86:12–21
  20. Mirza AM , Correa PN , Axelrad AA . Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera . Blood . 1995;86:877–882
  21. Means RT , Krantz SB , Sawyer ST , Gilbert HS . Erythropoietin receptors in polycythemia vera . J Clin Invest . 1989;84:1340–1344
  22. Mirza AM , Ezzat S , Axelrad AA . Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro . Blood . 1997;89:1862–1869
  23. Adamson JW , Fialkow PJ , Murphy S , Prchal JF , Steinmann L . Polycythemia vera (Stem-cell and probable clonal origin of the disease) . N Engl J Med . 1976;295:913–916
  24. Cools J , DeAngelo DJ , Gotlib J , Stover EH , Legare RD , Cortes J , et al.   A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome . N Engl J Med . 2003;348:1201–1214
  25. Popovici C, Adelaide J, Ollendorff V, Chaffanet M, Guasch G, Jacrot M, et al  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13) . Proc Natl Acad Sci U S A . 1998;95:5712–5717
  26. Valent P , Akin C , Sperr WR , Horny HP , Metcalfe DD . Mast cell proliferative disorders (Current view on variants recognized by the World Health Organization) . Hematol Oncol Clin North Am . 2003;17:1227–1241
  27. Koury MJ , Sawyer ST , Brandt SJ . New insights into erythropoiesis . Curr Opin Hematol . 2002;9:93–100
  28. Mason-Garcia M , Beckman BS . Signal transduction in erythropoiesis . FASEB J . 1991;5:2958–2964
  29. Koury MJ , Bondurant MC . Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells . Science . 1990;248:378–381
  30. Krantz SB . Erythropoietin . Blood . 1991;77:419–434
  31. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin . Cell . 1993;74:227–236
  32. Wu H , Liu X , Jaenisch R , Lodish HF . Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor . Cell . 1995;83:59–67
  33. Michl P , Spoettl G , Engelhardt D , Weber MM . Alterations of the insulin-like growth factor system in patients with polycythemia vera . Mol Cell Endocrinol . 2001;181:189–197
  34. Neubauer H , Cumano A , Muller M , Wu H , Huffstadt U , Pfeffer K . Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis . Cell . 1998;93:397–409
  35. Huang LJ , Constantinescu SN , Lodish HF . The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor . Mol Cell . 2001;8:1327–1338
  36. Royer Y , Staerk J , Costuleanu M , Courtoy PJ , Constantinescu SN . Janus kinases affect thrombopoietin receptor cell surface localization and recycling . J Biol Chem . 2005;280:27251–27261
  37. Moliterno AR , Hankins WD , Spivak JL . Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera . N Engl J Med . 1998;338:572–580
  38. Moliterno AR , Spivak JL . Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera . Blood . 1999;94:2555–2561
  39. Kralovics R , Guan Y , Prchal JT . Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera . Exp Hematol . 2002;30:229–236
  40. Roder S , Steimle C , Meinhardt G , Pahl HL . STAT3 is constitutively active in some patients with polycythemia rubra vera . Exp Hematol . 2001;29:694–702
  41. Dai CH , Chung I-J , Krantz SB . Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB . Exp Hematol . 2005;33:152–158
  42. Ugo V , Marzac C , Teyssandier I , Larbret F , Lecluse Y , Debili N , et al.   Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera . Exp Hematol . 2004;32:179–187
  43. Komura E , Chagraoui H , Mansat de Mas V , Blanchet B , de Sepulveda P , Larbret F , et al.   Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis (Possible relationship with FKBP51 overexpression) . Exp Hematol . 2003;31:622–630
  44. Silva M , Richard C , Benito A , Sanz C , Olalla I , Fernandez-Luna JL . Expression of Bcl-x in erythroid precursors from patients with polycythemia vera . N Engl J Med . 1998;338:564–571
  45. Baxter EJ , Scott LM , Campbell PJ , East C , Fourouclas N , Swanton S , et al.   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders . Lancet . 2005;365:1054–1061
  46. James C , Ugo V , Le Couedic JP , Staerk J , Delhommeau F , Lacout C , et al.   unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera . Nature . 2005;434:1144–1148
  47. Levine RL , Wadleigh M , Cools J , Ebert BL , Wernig G , Huntly BJ , et al.   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis . Cancer Cell . 2005;7:387–397
  48. Kralovics R , Passamonti F , Buser AS , Te SS , Tiedt R , Passweg JR , et al.   A gain of function mutation of Jak2 in patients with myeloproliferative disorders . N Engl J Med . 2005;352:1779–1790
  49. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera . J Biol Chem . 2005;280:22788–22792
  50. Steensma DP , Dewald GW , Lasho TL , Powell HL , McClure RF , Levine RL , et al.   The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloprolioferative disorders and the myelodysplastic syndrome . Blood . 2005; on line, DOI 10.1182?,
  51. Luo H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM, et al  Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways . Mol Cell Biol . 1997;17:1562–1571
  52. Saharinen P , Takaluoma K , Silvennoinen O . Regulation of the Jak2 tyrosine kinase by its pseudokinase domain . Mol Cell Biol . 2000;20:3387–3395
  53. Saharinen P , Vihinen M , Silvennoinen O . Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain . Mol Biol Cell . 2003;14:1448–1459
  54. Lindauer K , Loerting T , Liedl KR , Kroemer RT . Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation . Protein Eng . 2001;14:27–37
  55. Lacronique V , Boureux A , Valle VD , Poirel H , Quang CT , Mauchauffe M , et al.   A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia . Science . 1997;278:1309–1312
  56. Shih LY, Lin TL, Lai CL, Dunn P, Wu JH, Wang PN, et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia . Blood . 2002;100:1596–1601
  57. Andrieux J , Demory MT , Caulier MT , Agape P , Wetterwald M , Bauters F , et al.   Karyotypic abnormalities in myelofibrosis following polycythemia vera . Cancer Genet Cytogenet . 2003;140:118–123
  58. Girault JA , Labesse G , Mornon JP , Callebaut I . The N-termini of FAK and JAKs contain divergent band 4.1 domains . Trends Biochem Sci . 1999;24:54–57
  59. Constantinescu SN , Keren T , Socolovsky M , Nam H , Henis YI , Lodish HF . Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain . Proc Natl Acad Sci U S A . 2001;98:4379–4384
  60. Dai CH , Krantz SB , Sawyer ST . Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells (a possible defect of phosphatase activity in polycythemia vera) . Blood . 1997;89:3574–3581
  61. Sui X , Krantz SB , Zhao Z . Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells . Blood . 1997;90:651–657
  62. Xu MJ , Sui X , Zhao R , Dai C , Krantz SB , Zhao ZJ . PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells . Blood . 2003;102:4354–4360
  63. Aravind L, Neuwals AF, Ponting CP: Sec14p-like domains in NF1 and Dbl-like proteins indicate lipid regulation of Ras and Rho signaling. Curr Biol 9:R195-R197, 999
  64. Qi Y , Zhao R , Cao H , Sui X , Krantz SB , Zhao ZJ . Purification and characterization of protein tyrosine phosphatase PTP-MEG2 . J Cell Biochem . 2002;6:79–89
  65. Zhao R , Fu X , Li Q , Krantz SB , Zhao ZJ . Specific interaction of protein tyrosine phosphatase-MEG2 with phosphatidylserine . J Biol Chem . 2003;278:22609–22614
  66. Kruger JM , Fukushima T , Cherepanov V , Borregaard N , Loeve C , Shek C , et al.   Protein-tyrosine phosphatase MEG2 is expressed by human neutrophils. Localization to the phagosome and activation by polyphosphoinositides . J Biol Chem . 2002;277:2620–2628
  67. Huynh H , Wang X , Li W , Bottini N , Williams S , Nika K , et al.   Homotypic secretory vesicle fusion induced by the protein tyrosine phosphatase MEG2 depends on polyphosphoinositides in T cells . J Immunol . 2003;171:6661–6671
  68. Neel BG , Gu H , Pao L . The “Shp”ing news (SH2 domain-containing tyrosine phosphatases in cell signaling) . Trends Biochem Sci . 2003;28:284–293
  69. Tsui HW , Siminovitch KA , Souza L , Tsui FWL . Motheaten and viable motheaten mice have mutations in the hematopoietic cell phosphatase gene . Nat Genet . 1993;4:124–129
  70. Shultz LD , Schweitzer PA , Rajan TV , Yi T , Ihle JN , Matthews RJ , et al.   Mutations at the murine motheaten locus are within the hematopoietic cell protein tyrosine phosphatase (Hcph) gene . Cell . 1993;73:1445–1454
  71. Klingmuller U , Lorenz U , Cantley LC , Neel BG , Lodish HF . Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals . Cell . 1995;80:729–738
  72. Asimakopoulos FA , Hinshelwood S , Gilbert JG , Delibrias CC , Gottgens B , Fearon DT , et al.   The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera . Oncogene . 1997;14:1215–1222
  73. Anderson P , Le Blanc K , Eriksson B-A , Samuelson J . No evidence for an altered mRNA expression or protein level of hematopoietic cell phosphatase in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythemia vera . Eur J Haematol . 1997;59:310–317
  74. Wickrema A , Chen F , Namin F , Yi T , Ahmad S , Uddin S , et al.   Defective expression of the SHP-1 phosphatase in polycythemia vera . Exp Hematol . 1999;27:1124–1132
  75. Spivak JL . The chronic myeloproliferative disorders (Clonality and clinical heterogeneity) . Semin Hematol . 2004;41(suppl 3):1–5
  76. Tartaglia M , Mehler EL , Goldberg R , Zampino G , Brunner HG , Kremer H , et al.   Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome . Nat Genet . 2001;29:465–468
  77. Tartaglia M , Niemeyer CM , Fragale A , Song X , Buechner J , Jung A , et al.   Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia . Nat Genet . 2003;34:148–150
  78. Loh ML , Vattikuti S , Schubbert S , Reynolds MG , Carlson E , Lieuw KH , et al.   Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis . Blood . 2004;103:2325–2331
  79. Tartaglia M , Martinelli S , Cazzaniga G , Cordeddu V , Iavarone I , Spinelli M , et al.   Genetic evidence for lineage- and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia . Blood . 2004;104:307–313
  80. Bentires-Alj M , Paez JG , David FS , Keilhack H , Halmos B , Naoki K , et al.   Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia . Cancer Res . 2004;64:8816–8820
  81. Feng GS . Shp-2 tyrosine phosphatase (Signaling one cell or many) . Exp Cell Res . 1999;253:47–54
  82. Jones CM , Dickinson TM . Polycythemia vera responds to imatinib mesylate . Am J Med Sci . 2003;325:149–152
  83. Silver RT . Imatinib mesylate (Gleevec) reduces phlebotomy requirements in polycythemia vera . Leukemia . 2003;17:1186–1187
  84. Oehler L , Jaeger E , Alexander ER , Sillaber C , Gisslinger H , Geissler K . Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro . Blood . 2003;102:2240–2242
  85. Bonifacino JS . Quality control of receptor-kinase signaling complexes . Dev Cell . 2002;2:1–2

 Supported in part by Grants No. HL076309 (Z.J.Z.), DK15555 (S.B.K.), and CA68485 (Vanderbilt-Ingram Cancer Center) from the National Institutes of Health, by la Ligue Nationale Contre le Cancer (Équipe Labellisée 2004, W.V.), Association de la Recherche Contre le Cancer and Fondation Contre la Leucémie (N.C.), and la Fédération Belge Contre le Cancer and the FNRS, Belgium (S.N.C.).

PII: S0037-1963(05)00079-X

doi: 10.1053/j.seminhematol.2005.05.019

Seminars in Hematology
Volume 42, Issue 4 , Pages 221-229 , October 2005

Article Tools

* Image Usage & Resolution